Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany
Br J Dermatol
.
2020 Aug;183(2):382-384.
doi: 10.1111/bjd.18958.
Epub 2020 Apr 13.
Authors
S Abraham
1
,
E Haufe
2
,
I Harder
3
,
A Heratizadeh
4
,
A Kleinheinz
,
A Wollenberg
,
E Weisshaar
,
M Augustin
,
F Wiemers
,
A Zink
,
T Biedermann
,
R von Kiedrowski
,
M Hilgers
,
M Worm
,
M Pawlak
,
M Sticherling
,
I Fell
,
C Handrick
,
K Schäkel
,
P Staubach
,
A Asmussen
,
B Schwarz
,
M Bell
,
K Neubert
,
I Effendy
,
T Bieber
,
B Homey
,
B Gerlach
,
E Tchitcherina
,
M Stahl
,
U Schwichtenberg
,
J Rossbacher
,
P Buck
,
M Mempel
,
S Beissert
1
,
T Werfel
4
,
S Weidinger
3
,
J Schmitt
2
;
TREATgermany study group
Affiliations
1
Department of Dermatology, University Allergy Center, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
2
Center of Evidence-Based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
3
Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
4
Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
PMID:
32068242
DOI:
10.1111/bjd.18958
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Registries
Substances
Antibodies, Monoclonal, Humanized
dupilumab
Grants and funding
Sanofi-Aventis Deutschland GmbH./International